Business
Disclosure of Information
Disclosure of Information.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n Sareum Holdings PLC\n16 August 2007\n\n\nFor immediate release 16 August 2007\n\n\n\n\n\n SAREUM HOLDINGS PLC\n\n (\"Sareum\" or the \"Company\")\n\n\n\n AIM Rule 26\n\n\n\n\nSareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery\nbusiness confirms that, for the purposes of AIM Rule 26, the Company's website\naddress is www.sareum.co.uk.\n\n\n\n\n\n\n\n\n\nFor further information:\n\n\nSareum Holdings 01223 497700\n\nTim Mitchell, Chief Executive Officer\n\nBuchanan Communications 020 7466 5000\n\nTim Anderson, Mary-Jane Johnson\n\nGrant Thornton Corporate Finance 020 7383 5100\n\nPhilip Secrett, Colin Aaronson\n\n\n\n\n\nNotes for editors:\n\nAbout Sareum Holdings plc\n\nSareum Holdings plc is a structure-based drug discovery business headquartered\nin Cambridge, UK. The Company was formed in August 2003 to discover new drugs\nfor the treatment of cancer. Sareum's unique approach aims to halve the time it\ntakes to discover new drug candidates.\n\nA structure-based approach to drug discovery relies on knowledge of the\nthree-dimensional structure of the proteins that cause disease. Once the\nstructure is known, potential drugs are designed to 'lock-in' to the protein\nwith the aim of reversing or arresting a disease's progression. Knowledge of\nthe structure of the potential drugs and how they 'lock-in' to their target\nprotein assists greatly in the development of high-quality drug candidates.\nDetermining structure is a complex task and requires leading-edge equipment and\nexperienced staff. Sareum's approach to structure determination utilises its\nproprietary protein expression platform in order to produce multiple recombinant\nproteins that accelerate structure determination using x-ray crystallography.\n\nOnce the structure is determined, the Company's innovative fragment screening\nplatform is used to identify novel chemical templates designed to interact with\nthe target protein. Sareum then uses its high-throughput medicinal chemistry\nplatform to rapidly optimise these molecules and develop the most promising into\npotential drug candidates.\n\nSareum aims to successfully deliver drug candidates for licensing to larger\npharmaceutical companies at the pre-clinical or early clinical trials stage.\nThis is funded by provision of its specialist drug discovery capabilities to\npartners in the pha...